Open original FDA record ↗Recall record
- FDA identifier
- Z-0123-2017
- Company in FDA record
- Randox Laboratories Ltd.
- FDA classification date
- Oct 18, 2016
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
According to the firm carry over was observed when the Lipase test is run directly before or after the LDL and Triglycerides assays. Customers are instructed to amend the running order for all instruments using these reagents to ensure Lipase is not place directly before or after LDL or Triglycerides. A correction was made to the IFU for the Lipase assay and all customers who purchased the Lipase kit in the USA were contacted with the updated instruction.
Source facts
- Action
- Randex Laboratories sent an Urgent Field Safety Notice letter dated June 17, 2016 to affected customers. The letter identified the affected product, problem and actions to be taken. Customers were instructed to complete and return the response section of this form technical.services@randox.com. For questions contact Randex Technical Service.
- Initiated
- 2016-08-02
- Root cause
- Nonconforming Material/Component
- Terminated
- 2017-09-07
- Distribution
- US Nationwide Distribution
- Recall number
- Z-0123-2017
- Recall status
- Terminated
- CDRH record ID
- 149666
- FDA classified
- 2016-10-18
- Recall event number
- 75207